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Monoclonal antibodies (mAbs) against cell surface antigens and receptors are instrumental in defining spe- 
cific membrane markers. mAbs GF 26.7.3 and MF 25.1 against human neutrophils modulated the activation 
mechanism of superoxide anion production induced by formyl-peptide and PMA in all subjects. However, 
treatment with mAb MF 25.1 of neutrophils from patients with rheumatoid arthritis did not have any effect. 
This may suggest that the antigen which MF 25.1 binds is absent in rheumatoid conditions. This confirms 
our previous data showing that defective expression of membrane components is associated with neutrophil 
dysfunction. 
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1. INTRODUCTION 
Neutrophils are essential in host defense against 
microorganisms, viruses and tumours but are also 
the major effector cells causing tissue damage in a 
wide variety of autoimmune disorders, such as 
rheumatoid arthritis. The molecular basis for this 
effect is not completely clear, but a relationship 
between defective protein components of the 
plasma membrane and the altered response of 
neutrophils to stimulation has been previously 
detected in rheumatoid subjects [l-4]. Similarly, 
other authors have shown defects in neutrophil 
function associated with a deficiency of plasma 
membrane glycoproteins [5-71. A number of 
Abbreviations: mAb, monoclonal antibody; PMA, 
phorbol 12-O-myristate 13-acetate; RA, rheumatoid ar- 
thritis; FMLP, N-formyl-methionyl-leucyl-phenyl- 
alanine; 02, superoxide anion; KRPG, Krebs-Ringer- 
phosphate containing 0.2% (w/v) glucose 
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mAbs have been described as modulating the 
response triggered by various stimulants [9, lo], 
suggesting that surface neutrophil antigens 
mediate cellular activation. mAbs GF 26.7.3 and 
MF 25.1 against human neutrophils, found to bind 
to cell surface antigens and to inhibit oxidative 
metabolism [ 111, were chosen to react with 
neutrophils from rheumatoid patients as probes of 
cellular responses under pathological conditions. 
2. MATERIALS AND METHODS 
mAbs GF 26.7.3, and MF 25.1, which specifical- 
ly react with human PMNs, were produced as 
described in [12,13]. Ascitic fluids GF 26.7.3 and 
MF 25.1 were fractionated by 45% ammonium 
sulfate, dialyzed against PBS (pH 7.4) at 4°C and 
the concentration determined at 280 nm. Serial 
dilutions of mAbs were made in PBS. The effect of 
mAb-neutrophil interaction was studied by expos- 
ing 1 x IO6 neutrophils in KRPG for 30 min at 
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37°C to antibody concentrations varying from 1 to 
100 pg/ml followed by washing the cells. Control 
PMNs were not treated with mAbs. 
Neutrophils were obtained from 20 healthy 
volunteers, 14 subjects with classical rheumatoid 
arthritis according to ARA criteria and 3 patients 
with psoriatic arthritis. All patients had taken no 
medication for the preceding 3 days. Cells were 
treated by dextran (Pharmacia) sedimentation of 
erythrocytes, and further purified by lymphocyte 
separation medium (Flow Labs); contaminating 
red cells were lysed with 0.86% NH&l. The cells 
(99-100% granulocytes) were washed twice and 
resuspended in KRPG (pH 7.4) to give 5-10 x lo6 
cells/ml. 
Superoxide anion release was monitored con- 
tinuously in a temperature-controlled spec- 
trophotometer (Zeiss PQ 11) as the reduction of 
ferricytochrome c, as described in [14]. At zero 
time, different amounts of each stimulant were 
added to 1 x lo6 neutrophilslml and the absor- 
bance change accompanying cytochrome c reduc- 
tion was monitored at 550 nm. The stimulants 
used were PMA and FMLP. Formyl-peptide was 
added to cell suspensions after 5 min incubation 
with 10pM cytochalasin B. All compounds were 
from Sigma. 
The ~il~onxon test was used in statistical 
evaluation of the differences between groups. 
3. RESULTS 
3.1, 05 production by neutrophils from normal 
and RA subjects 
As shown in [l I], no significant differences in 
0; generation was detected when neutrophils from 
healthy and RA subjects were stimulated by PMA 
and FMLP. The PMA concentration ranged from 
81 nM to 16.2pM and that of FMLP from 10pM 
to 10 nM; maximal 02 production was found to 
occur at 162 nM PMA and 1 PM FMLP and 
amounted to 24.6 +- 1 and 10.8 f 2 nmol 
Ot/5 min per IO6 neutrophils, respectively. 
3.2. Effect of mAbs on 05 production by 
neutrophils from normal and RA subjects 
The pre-incubation of 1 x lo6 neutrophils from 
healthy individuals with 15 pg/ml of MF 25.1 or 
GF 26.7.3 inhibited 02 production induced by 
PMA and FMLP. As shown in fig.1, the extent of 
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Fig.1. Effect of antibody treatment on 0: production 
induced by PMA and FMLP. 1 x lo6 neutrophils from 
normal subjects (empty columns) and rheumatoid 
patients (filled columns) were preincubated at 37°C for 
30 min with 15pglml MF 25.1 (A) or 15pglml GF 
26.7.3 (B). Activation of the Or generating system was 
induced by 0.162 FM PMA and 1 FM FMLP. Bars 
represent f SE of separate experiments performed in 
duplicate. * Difference between control and RA treated 
is statistically significant @ > 0.01). n, number of 
experiments. 
the inhibitory effect depended on both the cell 
stimulant and the mAb applied. GF 26.7.3 pro- 
duced 75% inhibition when the enzymatic complex 
was induced to release 02 by 1 FM FMLP. 
However, when neutrophils from RA patients were 
treated with MF 25.1 and then stimulated with 
PMA or FMLP to produce 02 no inhibition occur- 
red. After treatment of RA neutrophils with GF 
26.7.3 a significant difference in the antibody- 
mediated inhibitory effect was detectable. It is in- 
teresting to note that neutrophils from patients 
with psoriatic arthritis did not exhibit functional 
diversity after pre-treatment with either mAb (not 
shown), in comparison with normal cells. 
4. DISCUSSION 
The two mAbs GF 26.7.3 and MF 25.1, specific 
for antigens present on the human neutrophil 
membrane 112,131, were found to inhibit 0; 
release induced by PMA and formyl-peptide [l 11. 
The cell activators used mediate their biological ef- 
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fects via different mechanisms: FMLP interacts 
through its proper surface receptor [15] and PMA 
activates protein kinase C [ 161. We have previously 
shown that GF 26.7.3 and MF 25.1 bind to 
separate antigen determinants, therefore the in- 
hibition produced by the two mAbs could be at- 
tributed to interference with the stimulus-mediated 
process of activation of NADPH oxidoreductase 
rather than the functional inactivation of specific 
receptor sites. 
Neutrophils derived from RA patients show a 
significant decrease in inhibition of 02 generation 
in the presence of GF 26.7.3 and do not respond to 
pre-treatment with MF 25.1, demonstrating that 
the superoxide enzymatic complex is unaffected by 
this antibody. The results may suggest that in 
rheumatoid disease, most likely the surface antigen 
determinant reacting with mAb MF 25.1 is lost, 
this being consistent with previous findings of 
defective expression of neutrophil membrane pro- 
teins in RA. Thus, the mAb MF 25.1 is able to 
reveal altered neutrophil capacities by not reacting 
with the defective neutrophil population that 
characterize RA, an immunological disorder in 
which neutrophil dysfunction is not completely 
manifest. Anti-neutrophil mAb MF 25.1 might 
have some clinical use in diagnosis of RA since 
neutrophils from psoriatic arthritis, a very similar 
autoimmune disease, do not share this functional 
diversity. 
In conclusion, mAbs are a very useful tool in the 
study of neutrophil function in both normal and 
pathological conditions. 
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